We are live on ! Find out more
FATE icon

Fate Therapeutics
FATE

116 hedge funds and large institutions have $893M invested in Fate Therapeutics in 2018 Q3 according to their latest regulatory filings, with 27 funds opening new positions, 43 increasing their positions, 26 reducing their positions, and 14 closing their positions.

New
Increased
Maintained
Reduced
Closed

93% more first-time investments, than exits

New positions opened: 27 | Existing positions closed: 14

83% more capital invested

Capital invested by funds: $488M → $893M (+$405M)

65% more repeat investments, than reductions

Existing positions increased: 43 | Existing positions reduced: 26

33% more funds holding in top 10

Funds holding in top 10: 3 → 4 (+1)

14% more call options, than puts

Call options by funds: $2.77M | Put options by funds: $2.43M

13% more funds holding

Funds holding: 103 → 116 (+13)

5.85% more ownership

Funds ownership: 81.42% → 87.27% (+5.8%)

Holders
116
Holders Change
+13
Holders Change %
+12.62%
% of All Funds
2.65%
Holding in Top 10
4
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+33.33%
% of All Funds
0.09%
New
27
Increased
43
Reduced
26
Closed
14
Calls
$2.77M
Puts
$2.43M
Net Calls
+$335K
Net Calls Change
-$401K

Top Buyers

Rank Fund Capital Flow
1
RG
Redmile Group
California
+$43.8M
2
PHS
PFM Health Sciences
California
+$17.8M
3
DM
Deerfield Management
New York
+$13.9M
4
Fidelity Investments
Fidelity Investments
Massachusetts
+$12M
5
Citadel Advisors
Citadel Advisors
Florida
+$8.01M

Top Sellers

Rank Fund Capital Flow
1
Millennium Management
Millennium Management
New York
-$6.22M
2
Franklin Resources
Franklin Resources
California
-$2.04M
3
Morgan Stanley
Morgan Stanley
New York
-$1.85M
4
6CM
683 Capital Management
New York
-$1.11M
5
Canada Pension Plan Investment Board
Canada Pension Plan Investment Board
Ontario, Canada
-$907K
Name Holding Trade Value Shares
Change 		Change in
Stake
Two Sigma Advisers
26
Two Sigma Advisers
New York
$4.71M +$1.04M +87,900 +44%
Bank of New York Mellon
27
Bank of New York Mellon
New York
$4.34M -$281K -23,754 -8%
Federated Hermes
28
Federated Hermes
Pennsylvania
$4.08M +$2.96M +250,464 New
Morgan Stanley
29
Morgan Stanley
New York
$3.44M -$1.85M -156,021 -43%
Deutsche Bank
30
Deutsche Bank
Germany
$3.43M +$1.34M +113,386 +117%
ECM
31
Endurant Capital Management
California
$3.33M +$1.44M +121,761 +147%
VIA
32
Vident Investment Advisory
Georgia
$3.17M -$153K -12,976 -6%
Wells Fargo
33
Wells Fargo
California
$3.09M +$851K +71,940 +61%
MIM
34
Monashee Investment Management
Massachusetts
$2.62M – – –
Millennium Management
35
Millennium Management
New York
$2.59M -$6.22M -525,901 -77%
Neuberger Berman Group
36
Neuberger Berman Group
New York
$1.96M +$1.24M +105,000 +700%
SSA
37
Schonfeld Strategic Advisors
New York
$1.89M +$1.37M +116,100 New
Charles Schwab
38
Charles Schwab
California
$1.81M +$66.9K +5,660 +5%
Allianz Asset Management
39
Allianz Asset Management
Germany
$1.76M +$1.28M +108,132 New
SI
40
Sofinnova Investments
California
$1.71M +$1.24M +104,891 New
EGI
41
EAM Global Investors
California
$1.68M +$298K +25,236 +32%
Goldman Sachs
42
Goldman Sachs
New York
$1.62M +$856K +72,379 +265%
MAP
43
Moody Aldrich Partners
Massachusetts
$1.61M +$185K +15,614 +19%
Renaissance Technologies
44
Renaissance Technologies
New York
$1.55M +$1.12M +95,100 New
AA
45
ALPS Advisors
Colorado
$1.54M +$211K +17,818 +23%
N
46
Nuveen
North Carolina
$1.53M +$126K +10,619 +13%
TCIM
47
TIAA CREF Investment Management
New York
$1.52M -$48K -4,063 -4%
TA
48
Teachers Advisors
New York
$1.5M +$15.2K +1,283 +1%
Swiss National Bank
49
Swiss National Bank
Switzerland
$1.41M +$153K +12,900 +18%
EI
50
EAM Investors
California
$1.33M +$237K +20,062 +33%
1
2
3 4 5

FATE Hedge Fund Activity: Q3 2018 in Review

116 of the 4,374 institutional investors tracked by Wall St. Rank reported a position in Fate Therapeutics (FATE) for Q3 2018, worth a combined $893M — up 83% from $488M a quarter earlier.

Buyers outnumbered sellers: 27 funds opened new FATE positions and 14 closed out — a net gain of 13 holders — while 43 added to existing stakes and 26 trimmed.

The largest buyer was Redmile Group, adding an estimated $43.8M. The largest seller was Millennium Management, cutting an estimated $6.22M.

  • 116 institutional investors held Fate Therapeutics (FATE) as of Q3 2018, up from 103 in Q2 2018.
  • Funds reported $893M of Fate Therapeutics stock for Q3 2018, up 83% quarter-over-quarter.
  • 27 funds opened new Fate Therapeutics positions in Q3 2018 and 14 closed out, a net change of +13 holders.
  • The largest Fate Therapeutics buyer in Q3 2018 was Redmile Group, an estimated $43.8M added.
  • The largest Fate Therapeutics seller in Q3 2018 was Millennium Management, an estimated $6.22M sold.

Based on aggregated 13F filings for Q3 2018.